EP0321231B1 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques Download PDF

Info

Publication number
EP0321231B1
EP0321231B1 EP88311861A EP88311861A EP0321231B1 EP 0321231 B1 EP0321231 B1 EP 0321231B1 EP 88311861 A EP88311861 A EP 88311861A EP 88311861 A EP88311861 A EP 88311861A EP 0321231 B1 EP0321231 B1 EP 0321231B1
Authority
EP
European Patent Office
Prior art keywords
phenol
dyclonine
dyclonine hcl
antimicrobial
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP88311861A
Other languages
German (de)
English (en)
Other versions
EP0321231A1 (fr
Inventor
James Vincent Sorrentino
William Joseph Kelleher
Jeanne Olore Moye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richardson Vicks Inc
Original Assignee
Richardson Vicks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Vicks Inc filed Critical Richardson Vicks Inc
Priority to AT88311861T priority Critical patent/ATE73329T1/de
Publication of EP0321231A1 publication Critical patent/EP0321231A1/fr
Application granted granted Critical
Publication of EP0321231B1 publication Critical patent/EP0321231B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • This invention is directed to pharmaceutical compositions containing dyclonine hydrochloride (HCl) and phenol.
  • Dyclonine HCl chemically denoted as 3-piperidino-4′-butoxypropiophenone hydrochloride, is a well known anesthetic/analgesic agent for topical use on the mucous membranes of the mouth and throat (see Federal Register, Vol. 47, No. 101, Proposed Rules, pages 22810-13, 1982).
  • compositions of dyclonine HCl commercially available in the United States include and aqueous liquid spray containing 0.1% dyclonine HCl and solid lozenges containing 1.2 mg dyclonine HCl per lozenge for children and 3.0 mg per lozenge for adults (see Physicians' Desk Reference for Non-prescription Drugs, 8th Ed., 1987, pages 518-9).
  • the benefit of dyclonine HCl is that it provides long acting topical anesthetic relief.
  • the use of certain acids, particularly citric acid, to stabilize dyclonine HCl in anesthetic lozenges is reported in US-A-4,139,627.
  • dyclonine HCl is known to possess antimicrobial activity.
  • US-A-2,868,689 discloses stabilized aqueous preparations of dyclonine HCl (0.1-58) having topical anesthetic and antimicrobial action, the stabilization aspect being provided by the addition of chlorobutanol (0.1-0.5%).
  • Phenol is a known topical anesthetic, which has been used to treat minor sore mouth and sore throat pain.
  • the mode of action, fast acting but not long lasting, is that it desensitizes sensory nerve receptors present in the mucous membranes of the throat and oral cavity to exert its local anestheticeffect.
  • Previous dosage forms of administration have included lozenges containing 32.5 mg phenol per lozenge and aqueous solutions of 1.4% phenol for use as a mouthwash, rinse or gargle, which is expelled from the oral cavity after use, and as a throat spray (see Physicians' Desk Reference for Non-prescription Drugs, 8th Ed., 1987, pages 654-5).
  • phenol is known to possess antimicrobial activity.
  • a liquid pharmaceutical composition of matter for oral health care use arid having enhanced antimicrobial action comprising an aqueous-based orally acceptable pharmaceutical carrier having incorporated therein from 0.05 to 2.0 w/v percent of dyclonine hydrochloride and from 1.0 to 1.4 w/v percent of phenol, said composition having a pH of from 3 to 4.
  • the subject invention provides a pharmaceutical composition of matter for oral health care use which not only provides relief of pain in irritated mucous membranes of the mouth and throat, but also provides enhanced antimicrobial activity.
  • oral includes the throat and oral cavity with contiguous mucosal tissues. Accordingly, the composition of this invention has beneficial application in treating, for example, sore or bacteria infected throat, cough-irritated sore throat, and other oral ailments wherein the source of irritation is partly or wholly derived from microbial infection.
  • composition of this invention possesses antimicrobial action that is greater than the sum of that possessed by dyclonine HCl or phenol when used alone.
  • the enhanced antimicrobial action between dyclonine HCl and phenol is demonstrated in the following type experiment using Staphylococcus aureus, a gram-positive bacterium.
  • test formulation A five millimeter (ml) aliquot of the test formulation is dispensed into a clean 18 mm borosilicate glass test tube for the undiluted sample. Dilutions of the test formulation are prepared using sterile deionized water.
  • the inoculum suspension is prepared from an overnight growth of the challenge organism on appropriate media.
  • SCDA Soybean Casein Digest Agar
  • SCDA contains 15 grams/liter (g/L) Soybean Casein Digest Broth and 15 g/L agar.
  • One liter of the medium is autoclaved at 15 psi and 121 C for 30-40 minutes and approximately 25 ml per plate are poured into sterile disposable 100 x 15 mm polystyrene Petri dishes.
  • Surface growth from the overnight culture is transferred from the plate using a sterile wire loop to 6 ml of 0.85% sterile saline in a test tube.
  • the suspension is adjusted to an optical density at 540 nanometers (OD540) of 0.5 as read in a Spectronic 20 spectrophotometer.
  • OD540 optical density at 540 nanometers
  • This OD540 is equivalent to approximately 5 x 108 colony forming units (cfu)/ml for S. aureus .
  • the inoculum size is confirmed by serial dilution of the inoculum into Letheen broth and by plating dilutions onto SCDA using a spread plate technique.
  • the enhanced antimicrobial effect of phenol and dyclonine HCl in aqueous pharmaceutical preparations is illustrated in Table I by the indicated test results obtained in accordance with the Methodology.
  • the "Base Vehicle” and other test products are described hereinafter in Example 1.
  • ATCC American Tissue Culture Collection
  • the actual OD540 reading was 0.43 and the actual inoculum size was 5.7 x 106 cfu/ml.
  • the symbol "P” represents phenol, and the symbol “D” represents dyclonine hydrochloride.
  • the numerical symbols indicate the recorded cfu/ml at the indicated time interval as follows:
  • Test product containing 1.4% phenol shows complete kill by 30 seconds at full strength concentration and a two-fold dilution (1/2x). However, a four-fold dilution (1/4x) shows less antimicrobial effectiveness with a count of 10-100 cfu/ml being recorded even after 5 minutes.
  • Test product containing 0.1% dyclonine HCl shows some activity at full strength with complete kill by 3 minutes. However, no activity is recorded at either two-fold or four-fold dilutions.
  • Test product with both 1.4% phenol and 0.1% dyclonine HCl shows complete kill by 30 seconds at full strength, two-fold dilution and four-fold dilution. At the four-fold dilution, the combination product has a faster onset of action than either of the single entity products.
  • the test results demonstrate that the two actives together have more than an additive effect on the antimicrobial activity of the formulations.
  • Test product containing both 1.0% phenol and 0.1% dyclonine HCL shows a similar effect. With 1.0% phenol alone, diluted four-fold, a 1001-10,000 cfu/ml count is observed after 5 minutes; and the four-fold dilution of dyclonine HCl alone shows no effect. In contrast, the four-fold dilution of the combination of the two actives shows complete kill by 5 minutes.
  • the present invention thus provides a novel pharmaceutical composition of matter for oral health care use, wherein it is sought to elicit an antimicrobial response.
  • the combination of the two actives provides the benefit of both faster acting topical anesthetic activity attributable to the phenol and longer acting topical anesthetic activity attributable to the dyclonine HCl, particularly for the relief of sore throat or mouth conditions requiring antimicrobial treatment.
  • Said composition comprises the two essential active ingredients, dyclonine hydrochloride and phenol, in admixture with a pharmaceutically acceptable carrier.
  • the dyclonine HCl and phenol are incorporated into a liquid pharmaceutically acceptable carrier according to conventional pharmaceutical practices.
  • the carrier is an aqueous-based pharmaceutically acceptable carrier, that is, one wherein the entire or predominant solvent content is water.
  • aqueous-based pharmaceutically acceptable carrier that is, one wherein the entire or predominant solvent content is water.
  • the pH of the subject compositions utilizing an aqueous-based orally acceptable pharmaceutical carrier is from 3 to 4 and, preferably, from 3.2 to 3.6.
  • acid buffers consistent with conventional pharmaceutical practices are generally utilized such as, for example, citrate and phosphate buffers.
  • stabilized aqueous pharmaceutical compositions containing dyclonine HCl are heretofore known as, for example, in US-A-2,868,689. Accordingly, in a stable liquid pharmaceutiral composition for oral health care use comprising an aqueous-based orally acceptable pharmaceutical carrier having incorporated therein an effective topical anesthetic and antimicrobial amount of dyclonine HCl, the present invention provides the improvement comprising the incorporation therein of the herein mentioned amounts of phenol.
  • liquid preparations for oral health care purposes it is common practice to include such product enhancing optional additives as colorants, flavorants and co-solvents, which additives may affect the total solubility of the two actives in the final product.
  • a liquid composition of this invention having an aqueous-based orally acceptable pharmaceutical carrier has from 0.05 to 2.0 weight/volume (w/v) percent of dyclonine HCl and from 1.0 to 1.4 w/v percent of phenol incorporated into said carrier.
  • compositions of this invention may optionally contain one or more other known therapeutic agents, particularly those commonly utilized in oral health care preparations, such as, for example, other agents having local anesthetic or antimicrobial activity.
  • Other optional ingredients which are non-therapeutic and well known to the pharmacist's art may also be included in amounts generally known for such ingredients, for example, natural or artificial sweeteners, flavoring agents and colorants to provide a palatable and pleasant looking final product; ethyl alcohol, propylene glycol and glycerin as co-solvents; and other typical pharmaceutically acceptable ingredients commonly employed in compositions of this type.
  • the foregoing formulation represents the herein mentioned Base Vehicle, which is an aqueous-based orally acceptable pharmaceutical carrier without either the dyclonine HCl or the phenol.
  • Base Vehicle an aqueous-based orally acceptable pharmaceutical carrier without either the dyclonine HCl or the phenol.
  • P phenol
  • D dyclonine HCl
  • both phenol and dyclonine HCl are added to the Base Vehicle in the indicated percentages to provide the herein mentioned two respective test products with both P and D as combined actives, i.e., two respective embodiments of the compositions of this invention.
  • the antimicrobial effectiveness of combined phenol and dyclonine HCl on the yeast microorganism, Candida albicans is demonstrated in Table II, the indicated test results being obtained in accordance with the previously described Methodology with the following modifications.
  • the OD540 of 0.5 is approximately equivalent to 5 x 107 cfu/ml for C. albicans .
  • the actual OD540 was 0.63 and the actual inoculum size was 1.8 x 105.
  • the particular microorganism is C. albicans ATCC 10231. Other indicated symbols are as previously denoted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (3)

1. Composition pharmaceutique liquide pour soins d'hygiène de la bouche et ayant une action antimicrobienne accrue, cette composition comprenant un véhicule à base aqueuse, pharmaceutiquement acceptable pour voie orale, auquel sont incorpores de 0,05 à 2,0 % en poids/volume de chlorhydrate de dyclonine et de 1,0 à 1,4 % en poids/volume de phénol, ladite composition ayant un pH de 3 à 4.
2. Composition selon la revendication 1, dans laquelle le pH se situe entre 3,2 et 3,6.
3. Composition pharmaceutique liquide pour soins de la bouche, cette composition ayant une action anti-microbienne accrue et comprenant un vehicule pharmaceutique à base aqueuse, acceptable pour la voie orale, auquel sont incorporés environ 0,1 % en poids/volume de chlorhydrate de dyclonine et de 1,0 à 1,4 % en poids/volume de phenol, ladite composition ayant un pH de 3,4.
EP88311861A 1987-12-16 1988-12-15 Compositions pharmaceutiques Expired - Lifetime EP0321231B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT88311861T ATE73329T1 (de) 1987-12-16 1988-12-15 Pharmazeutische zusammensetzungen.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/133,834 US4808410A (en) 1987-12-16 1987-12-16 Pharmaceutical compositions containing dyclonine HC1 and phenol
US133834 1987-12-16

Publications (2)

Publication Number Publication Date
EP0321231A1 EP0321231A1 (fr) 1989-06-21
EP0321231B1 true EP0321231B1 (fr) 1992-03-11

Family

ID=22460497

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88311861A Expired - Lifetime EP0321231B1 (fr) 1987-12-16 1988-12-15 Compositions pharmaceutiques

Country Status (11)

Country Link
US (1) US4808410A (fr)
EP (1) EP0321231B1 (fr)
JP (1) JPH01265026A (fr)
KR (1) KR890009400A (fr)
AT (1) ATE73329T1 (fr)
AU (1) AU629803B2 (fr)
CA (1) CA1318599C (fr)
DE (1) DE3869088D1 (fr)
DK (1) DK701188A (fr)
NZ (1) NZ227339A (fr)
PH (1) PH24860A (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892877A (en) * 1987-10-27 1990-01-09 Richardson-Vicks Inc. Antitussive liquid compositions containing phenol
US4917894A (en) * 1988-06-29 1990-04-17 Beecham Inc. Rapid-onset long-duration oral anesthetic composition
ZA90341B (en) * 1989-01-23 1990-10-31 Merrell Dow Pharma Liquid pharmaceutical composition for piperidinoalkanol derivatives
US4931473A (en) * 1989-02-15 1990-06-05 Richardson-Vicks Inc. Anesthetic oral compositions
US5100898A (en) * 1990-01-25 1992-03-31 Richardson-Vicks Inc. Antitussive liquid compositions containing dyclonine
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
US5547657A (en) * 1994-10-11 1996-08-20 Eastman Chemical Company Low-irritation anesthetic and antiseptic mouth rinse
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US10179159B2 (en) 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
AU5286901A (en) 1999-10-22 2001-06-18 Transdermatech, Inc. Topical anesthetic formulation
US7144846B2 (en) * 2004-05-11 2006-12-05 Steris, Inc. Acidic phenolic disinfectant compositions
PL2552440T3 (pl) * 2010-03-30 2019-04-30 Helperby Therapeutics Ltd Nowa kombinacja i zastosowanie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868689A (en) * 1956-10-09 1959-01-13 Allied Lab Inc Pharmaceutical preparations containing dyclonine hydrochloride and chlorobutanol
US3203097A (en) * 1963-04-25 1965-08-31 Denver Chemical Mfg Company Germicidal dental pad
US4067997A (en) * 1975-05-21 1978-01-10 Med-Chem Laboratories Synergistic microbecidal composition and method
US4139627A (en) * 1977-10-06 1979-02-13 Beecham Inc. Anesthetic lozenges
DE2860482D1 (en) * 1977-11-07 1981-03-26 Beecham Inc Anaesthetic lozenges and method of preparing them
JPS5549317A (en) * 1978-10-02 1980-04-09 Dow Chemical Co Control of virus surrounded with phenylketones
US4624849A (en) * 1984-11-02 1986-11-25 The Procter & Gamble Company Antimicrobial lozenges
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process

Also Published As

Publication number Publication date
AU2700488A (en) 1989-06-22
CA1318599C (fr) 1993-06-01
AU629803B2 (en) 1992-10-15
PH24860A (en) 1990-12-26
US4808410A (en) 1989-02-28
KR890009400A (ko) 1989-08-01
DE3869088D1 (de) 1992-04-16
EP0321231A1 (fr) 1989-06-21
JPH01265026A (ja) 1989-10-23
DK701188D0 (da) 1988-12-16
ATE73329T1 (de) 1992-03-15
DK701188A (da) 1989-06-17
NZ227339A (en) 1990-09-26

Similar Documents

Publication Publication Date Title
US4927634A (en) Pharmaceutical compositions containing dyclonine HC1 and phenol
US10231994B2 (en) Selenium-containing compositions and uses thereof
US5560906A (en) Non-alcoholic antimicrobial mouthwash for removal of dental plaque
EP0321231B1 (fr) Compositions pharmaceutiques
TW200942262A (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
US20160199329A1 (en) Broad spectrum pharmacological composition for treatmentof various infections and diseases and methodsof use
WO2022088724A1 (fr) Composition de bain de bouche à substance active à base de thé vert et son procédé de préparation
JPH085800B2 (ja) 塩化リゾチ−ム及びグリチルリチン酸ジカリウム含有水溶液製剤
US8633194B2 (en) Pharmaceutical composition of piperazine derivatives
CN112545978A (zh) 具有持效抗幽门螺杆菌作用的口腔护理凝胶及其制备方法
JP3636611B2 (ja) 殺菌消毒剤組成物
JP2777148B2 (ja) 少なくとも１種の単細胞生物を阻害し，又は破壊する，弗素Ｆ▲上−▼及びリチウムＬｉ▲上＋▼を含む組成物
JP5013735B2 (ja) 眼粘膜適用製剤
EP1052991B1 (fr) Utilisation topicale du loperamide pour le traitement des infections microbielles
US10493050B2 (en) Broad spectrum pharmacological composition for treatmentof various infections and diseases and methodsof use
AU691177B2 (en) Liquid antacid compositions
RU2184534C2 (ru) Антисептические таблетки
RU2809005C1 (ru) Средство для ухода за полостью рта, содержащее гексапептид и хлоргексидин
WO2024016109A1 (fr) Composition de soins buccaux à base d'une substance active du thé et son procédé de préparation
JP2000229863A (ja) 咽頭疾患用組成物
JPH1179984A (ja) 口腔・咽喉疾患用液剤
US11351192B2 (en) De-colonization drug, preparation method therefor, and application thereof
JP2004026725A (ja) 固形製剤
JP2002161041A (ja) 感染症治療剤
KR20220008722A (ko) 카라기난을 포함하는 구강 청결용 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19891124

17Q First examination report despatched

Effective date: 19900817

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 73329

Country of ref document: AT

Date of ref document: 19920315

Kind code of ref document: T

ITF It: translation for a ep patent filed

Owner name: ING. C. GREGORJ S.P.A.

REF Corresponds to:

Ref document number: 3869088

Country of ref document: DE

Date of ref document: 19920416

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: RICHARDSON VICKS, INC.

EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 88311861.4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19961206

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19961211

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19961212

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19961218

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19961219

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19961223

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19961231

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19970214

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19970407

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19971215

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19971215

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19971215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19971216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19971231

Ref country code: FR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19971231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19971231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19971231

BERE Be: lapsed

Owner name: RICHARDSON-VICKS INC.

Effective date: 19971231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980701

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19971215

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19980701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980901

EUG Se: european patent has lapsed

Ref document number: 88311861.4

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051215